Biohaven Pharmaceutical
在场
Biohaven Pharmaceutical 的所有者是 Portage Biotech.
Portage Biotech 是一家在股票代码 PRTG (CA) 下上市的公司。
Portage Biotech 在 2 个国家有直接业务。Portage Biotech 拥有 3家子公司，其中包括 Biohaven Pharmaceutical、Pyramid Biosciences 和 Sentien Biotech。
他们在：
高管
查看带有其 130 名主要高管的组织结构图
Biohaven Pharmaceutical 搜索最多的简介
- Vlad Coric, Chief Executive Officer and Chairman of the Board
- John Childs, Director
- Bob Hugin, Director
创建提醒
跟踪 Biohaven Pharmaceutical 的高管变动
药店
Portage Biotech 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
药店 行业的其他推荐联系人
消息
Biohaven Pharmaceutical 的最新新闻稿
- Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
- Biohaven Announces Record Date for Anticipated Spin-Off
- Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
- Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
- American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
- Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
- Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
- Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
- Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
- Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
- View more press releases Close
通过电子邮件
